Glioma
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Glioma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
|
18985363 |
2008 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
|
19359588 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
|
19117336 |
2009 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We analyzed the genomic region spanning wild-type R132 of IDH1 by direct sequencing in 125 glial tumors.
|
19765000 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
|
19435942 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.
|
19996293 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The assay detected IDH mutations in biopsy material containing mostly glioma and in concomitant near-miss stereotactic core biopsies that were otherwise equivocal for the presence of glioma by light microscopy.
|
19915484 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to see whether the IDH1 codon 132 mutations occur in other human cancers besides glial tumors.
|
19378339 |
2009 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
|
19117336 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities.
|
19554337 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
The enzymatic activity of the proteins that were produced from normal and mutant IDH1 and IDH2 genes was determined in cultured glioma cells that were transfected with these genes.
|
19228619 |
2009 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH1 codon 132 sequencing was performed in a series of 404 patients with glioma (100 grade 2, 121 grade 3, and 183 grade 4 gliomas) and correlated with histology, genomic profile, methylguanyl methyltransferase (MGMT) promoter methylation status, and outcome.
|
19636000 |
2009 |
Glioma
|
0.700 |
Biomarker
|
disease |
CTD_human |
IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
|
19901110 |
2009 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the IDH1 gene at position R132 coding for the enzyme cytosolic isocitrate dehydrogenase are known in glioma and have recently been detected also in acute myeloid leukemia (AML).
|
20805365 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and accumulation of 2-hydroxyglutarate (2-HG).
|
20142433 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data also confirm the prognostic impact of IDH1/IDH2 mutation in gliomas whatever grade considered: patients harboring mutations of IDH1/IDH2 have an improved median overall survival.
|
20427748 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results were validated on an independent sample cohort, indicating that the IDH1 mutation spectrum may aid glioma subtype classification.
|
20077503 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.
|
21080178 |
2010 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations of both the IDH1 and IDH2 (isocitratedehydrogenase enzyme 1 and 2) genes have recently been described in cases of human glioma.
|
20847279 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.
|
21088844 |
2010 |
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Somatic mutations in the isocitrate dehydrogenase 1 gene (IDH1) occur at high frequency in gliomas and seem to be a prognostic factor for survival in glioblastoma patients.
|
20127344 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
1p/19q codeletion and IDH1 mutations are also useful to support and extend the histological classification of gliomas since they are strongly linked to oligodendroglial morphology and grade II/III gliomas, as opposed to glioblastoma, respectively.
|
20862485 |
2010 |
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
|
20174854 |
2010 |